Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Oct 25;7(43):70113-70127.
doi: 10.18632/oncotarget.12158.

BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis

Yaning Zhu  1 , Jian Wu  1 , Chengwan Zhang  2 , Suan Sun  1 , Jian Zhang  3 , Wenjie Liu  1 , Jian Huang  1 , Zhihong Zhang  4
Affiliations
Meta-Analysis

BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis

Yaning Zhu et al. Oncotarget. .

Abstract

BRCA mutations occur frequently in breast cancer (BC), but their prognostic impact on outcomes of BC has not been determined. We conducted an updated meta-analysis on the association between BRCA mutations and survival in patients with BC. Electronic databases were searched. The primary outcome measure was overall survival (OS), and the secondary outcome measures included breast cancer-specific survival (BCSS) and event-free survival (EFS). Hazard ratios (HR) and 95% confidence interval (CI) were abstracted and pooled with random-effect modeling. Data from 297, 402 patients with BC were pooled from 34 studies. The median prevalence rates of BRCA1 and BRCA2 mutations were 14.5% and 8.3%, respectively. BRCA mutations were associated with worse OS (BRCA1: HR = 1.69, 95% CI, 1.35 to 2.12, p < 0.001; BRCA2: HR = 1.50, 95% CI 1.03 to 2.19, p = 0.034). However, this did not translate into poor BCSS (BRCA1: HR = 1.14, 95% CI, 0.81 to 1.16, p = 0.448; BRCA2: HR = 1.16; 95% CI 0.82 to 1.66, p = 0.401) or EFS (BRCA1: HR = 1.10, 95% CI, 0.86 to 1.41, p = 0.438; BRCA2: HR= 1.09; 95% CI 0.81 to 1.47, p = 0.558). Several studies analyzed BRCA1 and BRCA2 mutations together and found no impact on OS (HR = 1.21; 95% CI, 0.73 to 2.00, p = 0.454) or EFS (HR = 0.94; 95% CI, 0.60 to 1.48, p = 0.787). BRCA1 and BRCA2 mutations were associated with poor OS in patients with BC, but had no significant impact on BCSS or EFS. An improved survival was observed in BC patients who had BRCA1 mutation and treated with endocrinotherapy. The results may have therapeutic and prognostic implications important for BRCA mutation carriers with BC.

Keywords: BRCA mutation; breast cancer; meta-analysis; survival; systematic review.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

None.

Figures

Figure 1
Figure 1. Flowchart of the study selection
Figure 2
Figure 2. Forest plot showing the association between BRCA1 mutation and survival
(A) Forest plot showing the association between BRCA1 and OS. (B) Forest plot showing the association between BRCA1 and BCSS. (C). Forest plot showing the association between BRCA1 and EFS.
Figure 3
Figure 3. Forest plot showing the association between BRCA2 and OS, BCSS and EFS
Figure 4
Figure 4. Begg's forest plot for OS of breast cancer with BRCA1 mutation (A) and BRCA2 mutation (B)
See this image and copyright information in PMC

References

    1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King M-C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1689. - PubMed
    1. Lenoir G, Lynch H, Watson P, Conway T, Lynch J, Narod S, Feunteun J. Familial breast-ovarian cancer locus on chromosome 17q12-q23. The Lancet. 1991;338:82–83. - PubMed
    1. Hall J, Friedman L, Guenther C, Lee M, Weber J, Black D, King M. Closing in on a breast cancer gene on chromosome 17q. American journal of human genetics. 1992;50:1235. - PMC - PubMed
    1. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science. 1994;265:2088–2090. - PubMed
    1. Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Molecular biology reports. 2012;39:2109–2118. - PubMed